Adverse childhood experiences (ACEs) have lasting impact on everyday emotional experiences in adulthood, with extant evidence linking ACEs to elevated emotional reactivity. However, findings are typically based on reactivity to daily events (i.e., stressors) and its moderation by ACEs (where individual adversities are summed into a total score), which overlooks adversity-specific associations and reactivity to other types of daily events. We therefore examine cumulative and individual ACEs as moderators of emotional reactivity to positive and negative daily events. Data were drawn from the National Study of Daily Experiences 2 (NSDE-II), collected 2004-2009, whereupon middle-aged and older adults ( = 1,994; = 58.61; range = 35-86; 57% female) reported daily events and affect on eight consecutive evenings. Multilevel models were used to estimate the moderating role of ACEs for within-person associations between positive/negative events and affect. We found that cumulative ACEs and a number of individual adversities (specifically those characterized by abuse but not by neglect or household challenge/dysfunction) were associated with emotional reactivity to positive negative daily events. That is, cumulative and abuse-based ACEs were associated with increased negative affect and/or decreased positive affect on days with a negative event . Our findings add to literature on the long-lasting and pervasive influence of early life experiences on everyday emotional experiences in adulthood. We discuss differences in reactivity to positive versus negative daily events and in cumulative versus adversity-specific associations as well as their theoretical and methodological implications. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1037/emo0001512 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.
J Dermatol
March 2025
Pfizer Japan Inc, Tokyo, Japan.
This subgroup analysis of the ALLEGRO phase 2b/3 study (NCT3732807) assessed the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). Patients aged ≥12 years with AA and ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (with or without 4-week 200-mg loading dose ["200/50" or "200/30"]) or 10 mg or placebo for 24 weeks, followed by a 24-week extension, in which patients initially assigned to placebo switched to 200/50 or 50 mg. In this subgroup analysis, Asian patients with response based on achieving a Severity of Alopecia Tool (SALT) score ≤20, SALT ≤10, ≥2-grade improvement or normal score on the eyebrow assessment (EBA) scale, and ≥2-grade improvement or normal score on the eyelash assessment (ELA) scale were evaluated through week 48.
View Article and Find Full Text PDFPatients' experiences with GLP1-RAs - a systematic review.
Scand J Prim Health Care
March 2025
Center for General Practice, University of Copenhagen, Copenhagen, Denmark.
Background: Obesity is a complex condition and a recognized public health challenge. Previous treatment options were associated with high failure rates, but recent trials have shown that significant weight loss can be achieved with GLP1-RAs. However, little is known about the patient's experiences with GLP1-RAs.
View Article and Find Full Text PDFA mixed-methods pilot study of domiciliary nasal high-flow therapy for breathlessness in people with chronic obstructive pulmonary disease who do not qualify for domiciliary long-term oxygen therapy.
Ther Adv Respir Dis
March 2025
Faculty of Medicine and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
Background: High-flow nasal oxygen (HFNO) therapy delivers humidified, heated air with flow rates of up to 60 L/min with oxygen entrained. HFNO has advantages over conventional oxygen therapy, including precise and reliable fraction of inspired oxygen delivery, therefore is recommended as first-line treatment for people with acute hypoxaemic respiratory failure.
Objectives: This pilot study aimed to determine the feasibility and acceptability of domiciliary nasal high flow (NHF) without entrained oxygen for people with chronic obstructive pulmonary disease (COPD) and severe breathlessness.
Glycemic Profiles and Hypoglycemia Awareness Among Pregnant Women with Gestational and Pre-existing Diabetes Referred to a Tertiary Center in Sulaimaniyah-Iraq in 2024.
Int J Endocrinol Metab
October 2024
Department of Medical Education, College of Medicine, University of Sulaimani, Sulaimaniyah, Kurdistan Region, Iraq.
Background: Hyperglycemia in pregnancy (HIP) comprises gestational diabetes mellitus (GDM) and pre-existing diabetes; type 1 diabetes (T1DM), type 2 diabetes (T2DM), and undetermined diabetes. Hyperglycemia in pregnancy leads to fetal and maternal complications.
Objectives: To observe and compare glycemic profiles (GP) and hypoglycemia awareness (HA) in women with GDM and pre-existing diabetes.
Effects of Dopamine Agonists on the Estradiol-Induced Prolactin Surge in Ovariectomized Female Wistar Han Rats.
Toxicol Sci
March 2025
Cerevel Therapeutics, LLC, Cambridge, MA.
Dopamine agonists (DAs) are approved for the treatment of hypodopaminergic pathologies, including Parkinson's disease, restless legs syndrome, and periodic limb movement disorder. During drug development, drugs acting on dopaminergic receptors are often associated with a rat-specific endocrine tumor response, including changes in fertility, which are ascribed to DA-induced suppression of pituitary prolactin release. Although these effects are not observed in or relevant to humans, given species differences in the effects of prolactin on reproductive organs, modeling DA-mediated changes in prolactin and the reproductive system remains important for preclinical drug development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!